DOCSLIB.ORG

2020 Medi-Cal

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 Medi-Cal Formulary Medi-Cal 2020 Medi-Cal DHCS Carve Out Medication List The medications listed below are excluded (not covered) by IEHP. However, you may still have access to these medications through your Medi-Cal fee-for-service (FFS) benefit. Please note that this list is updated often by Medi-Cal. Drugs may be added or deleted. For questions about a benefit or service listed here, please call Medi-Cal Support at 1-800-541-5555. Psychiatric Drugs Drug Name (Brand Name) Amantadine HCl Amantadine HCl ER Aripiprazole Aripiprazole lauroxil (Aristada Initio) Asenapine (Saphris) Benztropine Mesylate Brexpiprazole Cariprazine Chlorpromazine HCl Clozapine Fluphenazine Decanoate Fluphenazine HCl Haloperidol Haloperidol Decanoate Haloperidol Lactate Iloperidone (Fanapt) Isocarboxazid Lithium Carbonate Lithium Citrate Loxapine Succinate Loxapine Aerosol Powder Breath Activated (Adasuve) Lurasidone Hydrochloride Molindone HCl Olanzapine Olanzapine Fluoxetine HCl Olanzapine Pamoate Monohydrate (Zyprexa Relprevv) Paliperidone (Invega) Paliperidone Palmitate (Invega Sustenna) Paliperidone Palmitate (Invega Trinza) Perphenazine Phenelzine Sulfate Pimavanserin (Nuplazid) Pimozide Updated 01/07/2020 (v14) 1 Drug Name (Brand Name) Quetiapine Risperidone Risperidone ER injectable suspension (Perseris) Risperidone Microspheres Selegiline (transdermal only) Thioridazine HCl Thiothixene Thiothixene HCl Tranylcypromine Sulfate Trifluoperazine HCl Trihexyphenidyl Ziprasidone HCl Ziprasidone Mesylate AIDS Drugs Drug Name (Brand Name) Abacavir/Lamivudine Abacavir Sulfate Abacavir Sulfate/Dolutegravir/Lamivudine (Triumeq) Atazanavir Sulfate Atazanavir/Cobicistat (Evotaz) Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) Cobicistat (Tybost) Darunavir Ethanolate Darunavir/Cobicistat (Prezcobix) Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Symtuza) Delavirdine Mesylate Dolutegravir (Tivicay) Dolutegravir/Lamivudine (Dovato) Dolutegravir/ Rilpivirine (Juluca) Doravine (Pifeltro) Doravirine/ Lamivudine/ Tenofovir disoproxil fumarate (Delstrigo) Efavirenz Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (Atripla) Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate (Symfi LO) Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate (Symfi) Elvitegravir (Vitekta) Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (Stribild) Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide (Genvoya) Emtricitabine/Rilpivirine/Tenofovir Alafenamide (Odefsey) Emtricitabine/Rilpivirine/ Tenofovir Disoproxil Fumarate (Complera) Emtricitabine/Tenofovir Alafenamide (Descovy) Emtricitabine Enfuvirtide Etravirine Fosamprenavir Calcium 2 Drug Name (Brand Name) Ibalizumab-uiyk (Trogarzo) Indinavir Sulfate Lamivudine Lamivudine/Tenofovir Disoproxil Fumarate (Cimduo) Lamivudine/ Tenofovir Disoproxil Fumarate (Temixys) Lopinavir/Ritonavir Maraviroc Nelfinavir Mesylate Nevirapine Raltegravir Potassium Rilpivirine Hydrochloride Ritonavir Saquinavir Saquinavir Mesylate Stavudine Tenofovir Alafenamide (Vemlidy) Tenofovir Disoproxil-Emtricitabine Tenofovir Disoproxil Fumarate Tipranavir Zidovudine/Lamivudine Zidovudine/Lamivudine/ Abacavir Sulfate Alcohol, Heroin Detoxification, and Dependency Treatment Drugs Drug Name (Brand Name) Acamprosate Calcium Buprenorphine HCl Buprenorphine Extended-Release Inj (Sublocade) Buprenorphine HCl (Belbuca) Buprenorphine Implant (Probuphine) Buprenorphine/Naloxone HCl Disulfiram (Antabuse) Lofexidine Hydrochloride (Lucemyra) Naloxone HCl Naltrexone (oral) Naltrexone Microsphere Injectable Suspension (Vivitrol) Blood Factor Products Drug Name (Brand Name) Antihemophilic factor VIII/von Willebrand factor complex (human) Anti-inhibitor Coagulation factor X (human) Factor VIIa (antihemophilic factor, recombinant) Factor VIII (antihemophilic factor, human) Factor VIII (antihemophilic factor, recombinant) 3 Drug Name (Brand Name) Factor VIII (antihemophilic factor, recombinant) (Novoeight) Factor IX (antihemophilic factor, purified, nonrecombinant) Factor IX (antihemophilic factor, recombinant) Factor IX (antihemophilic factor, recombinant) (Rixubis) Factor IX (antihemophilic factor, recombinant), glycopegylated, (Rebinyn), Per IU Factor IX complex Factor XIII (antihemophilic factor, human) Factor XIII A-Subunit (recombinant) Hemlibra Hemophilia clotting factor, not otherwise classified Injection, factor VIII (antihemophilic factor, recombinant) (Obizur) Injection, factor VIII, fc fusion (recombinant) Injection, factor VIII, fc fusion protein (recombinant) Injection, factor IX fusion protein (recombinant) Von Willebrand factor complex (human), Wilate Von Willebrand factor complex (Humate-P) 4 IEHP Medi-Cal 2020 Formulary Based on American Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic Classification Table of Contents ANTIHISTAMINE DRUGS - DRUGS FOR ALLERGY .................................................................................... 6 ANTI-INFECTIVE AGENTS - DRUGS FOR INFECTIONS ............................................................................ 8 ANTINEOPLASTIC AGENTS - DRUGS FOR CANCER ............................................................................... 14 ANTITOXINS,IMMUNE GLOB,TOXOIDS,VACCINES - DRUGS FOR THE IMMUNE SYSTEM ........ 16 AUTONOMIC DRUGS - DRUGS FOR THE NERVOUS SYSTEM ............................................................... 22 BLOOD FORMATION, COAGULATION, THROMBOSIS - DRUGS FOR THE BLOOD ....................... 28 CARDIOVASCULAR DRUGS - DRUGS FOR THE HEART ......................................................................... 31 CENTRAL NERVOUS SYSTEM AGENTS - DRUGS FOR THE NERVOUS SYSTEM ............................. 46 CONTRACEPTIVES (E.G. FOAMS, DEVICES) - DRUGS FOR WOMEN .................................................. 58 DEVICES - MEDICAL SUPPLIES AND DURABLE MEDICAL EQUIPMENT ......................................... 59 DIAGNOSTIC AGENTS ....................................................................................................................................... 60 ELECTROLYTIC, CALORIC, AND WATER BALANCE ............................................................................. 60 EYE, EAR, NOSE AND THROAT (EENT) PREPS. ......................................................................................... 65 GASTROINTESTINAL DRUGS ......................................................................................................................... 70 GASTROINTESTINAL DRUGS - DRUGS FOR THE STOMACH ............................................................... 71 GOLD COMPOUNDS ........................................................................................................................................... 75 HEAVY METAL ANTAGONISTS - DRUGS TO REDUCE IRON ................................................................ 75 HORMONES AND SYNTHETIC SUBSTITUTES - HORMONES ................................................................ 75 MISCELLANEOUS THERAPEUTIC AGENTS ............................................................................................... 87 OXYTOCICS - DRUGS FOR WOMEN ............................................................................................................. 92 RESPIRATORY TRACT AGENTS - DRUGS FOR THE LUNGS ................................................................. 92 SKIN AND MUCOUS MEMBRANE AGENTS - DRUGS FOR THE SKIN .................................................. 99 SMOOTH MUSCLE RELAXANTS - DRUGS TO RELAX MUSCLES ....................................................... 108 VITAMINS ........................................................................................................................................................... 109 INDEX ................................................................................................................................................................... 115 5 IEHP Medi-Cal 2020 Formulary Based on American Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic Classification CURRENT AS OF 2/1/2020 Coverage Requirements Prescription Drug Name Drug Tier and Limits ANTIHISTAMINE DRUGS - DRUGS FOR ALLERGY ETHANOLAMINE DERIVATIVES - DRUGS FOR ALLERGY BENADRYL ALLERGY ORAL LIQUID 12.5 MG/5 ML F QL (240 ML per 30 days) (diphenhydramine) CHILDREN'S WAL-DRYL ALLERGY ORAL PREFILLED F QL (240 ML per 30 days) SPOON 12.5 MG/5 ML (diphenhydramine) diphenhydramine hcl oral capsule 25 mg, 50 mg F QL (100 EA per 30 days) diphenhydramine hcl oral elixir 12.5 mg/5 ml F QL (240 ML per 30 days) diphenhydramine hcl oral syrup 12.5 mg/5 ml F QL (240 ML per 30 days) diphenhydramine hcl oral tablet 25 mg F QL (100 EA per 30 days) NIGHTTIME SLEEP AID (DIPHEN) ORAL TABLET 25 MG F QL (100 EA per 30 days) (diphenhydramine) FIRST GEN. ANTIHIST. DERIVATIVES, MISC. - DRUGS FOR ALLERGY cyproheptadine oral syrup 2 mg/5 ml F cyproheptadine oral tablet 4 mg F FIRST GENERATION ANTIHISTAMINES - DRUGS FOR ALLERGY BENADRYL ALLERGY ORAL LIQUID 12.5 MG/5 ML F QL (240 ML per 30 days) (diphenhydramine) CHILDREN'S WAL-DRYL ALLERGY ORAL PREFILLED F QL (240 ML per 30 days) SPOON 12.5 MG/5 ML (diphenhydramine) chlorpheniramine maleate oral tablet 4 mg F chlorpheniramine maleate oral tablet extended release 12 mg F cyproheptadine oral syrup 2 mg/5 ml F cyproheptadine oral tablet 4 mg F diphenhydramine hcl oral capsule 25 mg, 50 mg F QL (100 EA per 30 days) diphenhydramine hcl oral elixir 12.5 mg/5 ml F QL (240 ML per 30 days) diphenhydramine hcl oral syrup 12.5 mg/5 ml F QL (240 ML per 30 days) diphenhydramine hcl oral tablet 25 mg F QL (100 EA per 30 days)
Load more

Recommended publications
  • Ophthalmic Adverse Effects of Nasal Decongestants on an Experimental
    A RQUIVOS B RASILEIROS DE ORIGINAL ARTICLE Ophthalmic adverse effects of nasal decongestants on an experimental rat model Efeitos oftálmicos adversos de descongestionantes nasais em modelo experimental com ratos Ayse Ipek Akyuz Unsal1, Yesim Basal2, Serap Birincioglu3, Tolga Kocaturk1, Harun Cakmak1, Alparslan Unsal4, Gizem Cakiroz5, Nüket Eliyatkın6, Ozden Yukselen7, Buket Demirci5 1. Department of Ophthalmology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 2. Department of Otorhinolaringology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 3. Department of Pathology, Veterinary Faculty, Adnan Menderes University, Aydin, Turkey. 4. Department of Radiology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 5. Department of Medical Pharmacology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 6. Department of Medical Pathology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 7. Department of Pathology, Aydin State Hospital, Aydin, Turkey. ABSTRACT | Purpose: To investigate the potential effects of cause ophthalmic problems such as dry eyes, corneal edema, chronic exposure to a nasal decongestant and its excipients cataracts, retinal nerve fiber layer, and vascular damage in on ocular tissues using an experimental rat model. Methods: rats. Although these results were obtained from experimental Sixty adult male Wistar rats were randomized into six groups. animals, ophthalmologists should keep in mind the potential The first two groups were control (serum physiologic) and ophthalmic adverse effects of this medicine and/or its excipients Otrivine® groups. The remaining four groups received the and exercise caution with drugs containing xylometazoline, Otrivine excipients xylometazoline, benzalkonium chloride, ethylene diamine tetra acetic acid, benzalkonium chloride and sorbitol, and ethylene diamine tetra acetic acid. Medications sorbitol for patients with underlying ocular problems.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • Review of the Existing Recommendations for Essential Medicines for Ear, Nose and Throat Conditions in Adults and Children and Suggested Modifications
    REVIEW OF THE EXISTING RECOMMENDATIONS FOR ESSENTIAL MEDICINES FOR EAR, NOSE AND THROAT CONDITIONS IN ADULTS AND CHILDREN AND SUGGESTED MODIFICATIONS 2012 Shelly Chadha, Andnet Kebede Prevention of Blindness and Deafness, World Health Organization REVIEW OF THE EXISTING RECOMMENDATIONS FOR ESSENTIAL MEDICINES (Ear, Nose and Throat conditions) FOR USE IN ADULTS AND CHILDREN AND SUGGESTED MODIFICATIONS Context: The WHO Essential Medicines List includes a section for ENT conditions in children. The current section does not make any reference to medicines and dosages recommended for adults. As most of the conditions for which the listed medicines are indicated, are common in adults, the list needs to be appropriately reviewed in that context. Methodology: Each of the medicines listed in the EML for children was reviewed to consider its appropriateness for inclusion in the EML for adults. The recommended dosages for adults and children were also considered. Recommendations: The medicine list should include a list for adults as well as children. The list for adults should include Xylometazoline hydrochloride nasal spray 0.1%. It should be stated that the medicine (xylometazoline nasal spray) should not be used for prolonged periods of time, unless specifically advised and under medical supervision. The adult list should also include the other medicines mentioned in the list of children, i.e.: o Ciprofloxacin ear drops: 0.3%, as hydrochloride, for tropical use. o Aectic acid ear drops, 2% in alcohol, for topical use. Budesonide nasal spray listed in the EML for children needs greater, in depth review, which may be considered for the next EML update. 1 Xylometazoline Hydrochloride nasal spray Indications: Nasal congestion is obstruction of nasal passages, mainly caused by mucosal inflammation due to increased venous engorgement, nasal secretions and tissue swelling.
    [Show full text]
  • Conceptual Model for Using Imidazoline Derivative Solutions in Pulpal Management
    Journal of Clinical Medicine Review Conceptual Model for Using Imidazoline Derivative Solutions in Pulpal Management Robert S. Jones Division of Pediatric Dentistry, Department of Developmental & Surgical Sciences, School of Dentistry, University of Minnesota, Minneapolis, MN 55455, USA; [email protected] Abstract: Alpha-adrenergic agonists, such as the Imidazoline derivatives (ImDs) of oxymetazoline and xylometazoline, are highly effective hemostatic agents. ImDs have not been widely used in dentistry but their use in medicine, specifically in ophthalmology and otolaryngology, warrants consideration for pulpal hemostasis. This review presents dental healthcare professionals with an overview of ImDs in medicine. ImD solutions have the potential to be more effective and biocompatible than existing topical hemostatic compounds in pulpal management. Through a comprehensive analysis of the pharmacology of ImDs and the microphysiology of hemostasis regulation in oral tissues, a conceptual model of pulpal management by ImD solutions is presented. Keywords: hemostasis; alpha-adrenergic agonists; imidazoline; oxymetazoline; nasal; dental pulp; mucosa; apexogenesis; pulpotomy; direct pulp cap; dentistry 1. Overview Citation: Jones, R.S. Conceptual The purpose of this review is to formulate a conceptual model on the potential man- Model for Using Imidazoline agement of pulpal tissue by imidazoline derivatives (ImDs) based on a review of the Derivative Solutions in Pulpal literature that examines the hemostatic properties and mechanistic actions of these com- Management. J. Clin. Med. 2021, 10, 1212. https://doi.org/10.3390/ pounds in other human tissues. Commercial ImDs are formulated in solution with an- jcm10061212 timicrobial preservatives in order to act as ‘parenteral topical agents’ and used to manage ophthalmic inflammation, nasal congestion, and to control bleeding during otolaryngology Academic Editor: Rosalia surgery [1,2].
    [Show full text]
  • Transient Mydriasis Due to Opcon-A
    Open Access Austin Journal of Clinical Ophthalmology Special Article - Ophthalmology: Clinical Cases and Images Transient Mydriasis Due to Opcon-A Hava Donmez Keklikoglu1, Aubrey Gilbert2 and Nurhan Torun3* Abstract 1Department of Neurology, Ataturk Education and Opcon-A (pheniramine maleate/ naphazoline hydrochloride) is a topical Research Hospital, Turkey decongestant and antihistamine combination that is used to treat ocular allergies. 2Department of Ophthalmology, Massachusetts Eye and It is sold as an over the counter eye drop and is generally associated with very Ear Infirmary, USA few side effects. It may, however, cause mydriasis in some patients, though this 3Division of Ophthalmology, Department of Surgery, Beth is not a well-recognized occurrence. We present three cases in which transient Israel Deaconess Medical Center, USA mydriasis was attributed to Opcon-A use and emphasize consideration of this *Corresponding author: Nurhan Torun, Division drug in the differential diagnosis of temporary pupillary dilation. of Ophthalmology, Department of Surgery, Beth Israel Keywords: Transient mydriasis; Anisocoria; Naphazoline; Pheniramine; Deaconess Medical Center, 330 Brookline Avenue, Opcon-A Boston, MA 02215, USA Received: April 30, 2015; Accepted: May 04, 2015; Published: May 06, 2015 Case Reports the eye. Based on this history and his normal exam he was diagnosed with pharmacological mydriasis. He was advised not to use Opcon-A Case 1 and his pupillary dilation did not recur. A 29-year-old man was seen in Ophthalmology Clinic for a dilated left pupil which he had noted a few hours earlier on the day Case 3 of presentation. He had no other acute complaints. His past medical A 24-year-old woman was seen in Ophthalmology Clinic for history was notable for asthma for which he occasionally used an three separate episodes of transient right pupillary dilation lasting a inhaler.
    [Show full text]
  • Anti-Hypotensive Effects of M6434, an Orally Active a 1-Adrenoceptor Agonist, in Rats
    Anti-Hypotensive Effects of M6434, an Orally Active a 1-Adrenoceptor Agonist, in Rats Tatsuroh Dabasaki, Masato Shimojo, Hiroshi Ishikawa and Akio Uemura Fuji Central Research Laboratory, Mochida Pharmaceutical Co., Ltd., 722 Jimba-aza-Uenohara, Gotemba, Shizuoka 412, Japan Received December 19, 1991 Accepted February 17, 1992 ABSTRACT-The anti-hypotensive effects of M6434 were evaluated and compared with those of other orally active sympathomimetics in rats. Oral administration of M6434 (0.5-2.0 mg/kg) and midodrine (1.0 5.0 mg/kg) also produced a dose-related increase in mean arterial pressure in normotensive rats. The pressor effect of M6434 was about 4 times more potent than that of midodrine. Both M6434 and midodrine caused a dose-dependent decrease in heart rate. The pressor effect of M6434 (1.0 mg/kg) did not diminish after its repeated administration for 7 days. The pretreatment with M6434 (0.5 1.0 mg/kg) and midodrine (2.0 5.0 mg/kg) improved the orthostatic index in the experimental model of postural hypotension in rats. The effect of M6434 on postural hypotension was about 5 times more po tent than that of midodrine. Intravenously injected M6434 (3-300pg/kg) produced a dose-dependent increase in the blood pressure of pithed rats. These results suggest that M6434 possesses a potent anti hypotensive activity which is superior to that of midodrine, and M6434 may be useful in the treatment of essential and postural hypotension. Keywords: M6434, a 1-Agonist, Midodrine, Postural hypotension, Orthostatic index M6434, 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imida in clinical therapy.
    [Show full text]
  • Effectiveness of Midodrine Treatment in Patients with Recurrent Vasovagal
    Europace (2011) 13, 1639–1647 CLINICAL RESEARCH doi:10.1093/europace/eur200 Syncope and Implantable Loop Recorders Effectiveness of Midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial) Downloaded from Jacobus J.C.M. Romme1, Nynke van Dijk2, Ingeborg K. Go-Scho¨ n3,4, Johannes B. Reitsma1, and Wouter Wieling3* 1Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands; 2Department of General Practice/ Family Medicine, 3 4 Academic Medical Center, Amsterdam, The Netherlands; Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands; and Bmeye Cardiovascular http://europace.oxfordjournals.org/ Monitoring B.V., Academic Medical Center, Amsterdam, The Netherlands Received 26 January 2011; accepted after revision 2 June 2011; online publish-ahead-of-print 13 July 2011 Aims Initial treatment of vasovagal syncope (VVS) consists of advising adequate fluid and salt intake, regular exercise, and physical counterpressure manoeuvres. Despite this treatment, up to 30% of patients continue to experience regular episodes of VVS. We investigated whether additional Midodrine treatment is effective in these patients. ..................................................................................................................................................................................... Methods In our study, patients with at least three syncopal and/or severe pre-syncopal recurrences during non-pharmacologi- and results cal treatment were eligible to receive double-blind cross-over treatment starting either with Midodrine or placebo. at Universiteit van Amsterdam on November 15, 2011 Treatment periods lasted for 3 months with a wash-out period of 1 week in-between. At baseline and after each treatment period, we collected data about the recurrence of syncope and pre-syncope, side effects, and quality of life (QoL).
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Oxymetazoline
    Oxymetazoline This sheet talks about exposure to oxymetazoline pregnancy and while breastfeeding. This information should not take the place of medical care and advice from your healthcare provider. What is oxymetazoline? Oxymetazoline is a medication that is used in nasal sprays (sprayed into nostrils) and topical preparations (applied to skin). Oxymetazoline has been used to treat nasal congestion, eye inflammation, and skin redness. Oxymetazoline works by constricting blood vessels (makes the blood vessels smaller). Oxymetazoline can be found in prescription products and in many over the counter products. Some examples are: Afrin®, Dristan®, Nostrilla®, Rhofade®, and Vicks®. I use oxymetazoline. Can it make it harder for me to get pregnant? Studies have not been done in women to see if oxymetazoline could make it harder to get pregnant. I just found out that I am pregnant. Should I stop taking oxymetazoline? Talk with your healthcare providers before making any changes to this medication. Does taking oxymetazoline increase the chance for miscarriage? Miscarriage can occur in any pregnancy. Studies have not been done to see if oxymetazoline increases the chance for a miscarriage. Does taking oxymetazoline in the first trimester increase the chance of birth defects? In every pregnancy, a woman starts out with a 3-5% chance of having a baby with a birth defect. This is called her background risk. A small number of studies on oxymetazoline use have not found that oxymetazoline increases the chance of birth defects. Could taking oxymetazoline in the second or third trimester cause other pregnancy complications? Oxymetazoline did not affect uterine blood flow in 12 pregnancies when the healthy mother was given a one-time nasal spray dose.
    [Show full text]
  • ADD/ADHD: Strattera • Allergy/Anti-Inflammatories
    EXAMPLES OF PERMITTED MEDICATIONS - 2015 ADD/ADHD: Strattera Allergy/Anti-Inflammatories: Corticosteroids, including Decadron, Depo-Medrol, Entocort, Solu-Medrol, Prednisone, Prednisolone, and Methylprednisolone Anesthetics: Alcaine, Articadent, Bupivacaine HCI, Chloroprocaine, Citanest Plain Dental, Itch-X, Lidocaine, Marcaine, Mepivacaine HCI, Naropin, Nesacaine, Novacain, Ophthetic, Oraqix, Paracaine, Polocaine, Pontocaine Hydrochloride, PrameGel, Prax, Proparacaine HCI, Ropivacaine, Sarna Ultra, Sensorcaine, Synera, Tetracaine, Tronothane HCI, and Xylocaine Antacids: Calci-Chew, Di-Gel, Gaviscon, Gelusil, Maalox, Mintox Plus, Mylanta, Oyst-Cal 500, Rolaids, and Tums Anti-Anxiety: Alprazolam, Atarax, Ativan, Buspar, Buspirone HCI, Chlordiazepoxide HCI, Clonazepam, Chlorazepate Dipotassium, Diastat, Diazepam, Hydroxyzine, Klonopin, Librium, Lorazepam, Niravam, Tranxene T-tab, Valium, Vistaril, and Xanax Antibiotics: Acetasol HC, Amoxil, Ampicillin, Antiben, Antibiotic-Cort, Antihist, Antituss, Avelox, Ceftazidime, Ceftin, Cefuroxime Axetil, Ceptaz, Cleocin, Cloxapen, Cortane-B Aqueous, Cortic, Cresylate, Debrox, Doryx, EarSol-HC, Fortaz, Gantrisin, Mezlin, Moxifloxacin, Neotic, Otocain, Principen, Tazicef, Tazidime, Trioxin, and Zyvox Anti-Depressants: Adapin, Anafranil, Asendin, Bolvidon, Celexa, Cymbalata, Deprilept, Effexor, Elavil, Lexapro, Luvox, Norpramin, Pamelor, Paxil, Pristiq, Prozac, Savella, Surmontil, Tofranil, Vivactil, Wellbutrin, Zoloft, and Zyban Anti-Diabetics: Actos, Amaryl, Avandia, Glipizide, Glucophage,
    [Show full text]
  • OCUREST Is Indicated For
    1. Generic Names Phenylephrine Naphazoline hydrochloride Menthol Camphor 2. Qualitative and Quantitative Composition Phenylephrine hydrochloride 0.12% w/v Naphazoline hydrochloride 0.05% w/v Menthol 0.005% w/v Camphor 0.01% w/v 3. Dosage form and strength Topical ophthalmic solution containing Phenylephrine hydrochloride 0.12% (0.12mg/100ml) and Naphazoline hydrochloride 0.05%(0.05mg/100ml) 4. Clinical particulars 4.1 Therapeutic indication OCUREST is indicated for: • Temporary relief of the minor eye symptoms of itching and redness caused by dust, smoke, sun glare, ragweed, pollen, grass, animal hair and dander. • Symptomatic relief to tearing, photophobia, redness, swelling, blepharospasm. • Controlling hyperaemia of the palpebral and bulbar conjunctiva resulting from bacterial, allergic and vernal conjunctivitis. 4.2 Posology and method of administration As directed by physician. 4.3 Contraindication The use of OCUREST is contraindicated in patients with narrow angle glaucoma. 4.4 Special warnings and precautions for use • The use of OCUREST should be with caution in patients with heart disease, hypertension or difficulty in urination due to enlargement of the prostate gland. • Prolonged use of decongestants is associated with rebound congestion. • The use of OCUREST should be discontinued If patient experiences pain, changes in vision, continued redness or irritation, or if the condition worsens, or persists for more than 72 hours. 4.5 Drug interactions Although, clinically significant drug-drug interactions between OCUREST and systemically administered drugs are not expected but may occur when co administered with monoamine oxidase inhibitors or beta blockers. 4.6 Use in special population Paediatric: Safety and efficacy in children has not been established.
    [Show full text]
  • Vasoconstrictive Decongestants: the Authorities’ Poisoning in Children
    Adverse Effects Editors’ Opinion Translated from Rev Prescrire January 2013; 33 (351): 25 Translated from Rev Prescrire February 2013; 33 (352): 103 Vasoconstrictive drugs: Vasoconstrictive decongestants: the authorities’ poisoning in children dithering leaves patients in danger FDA review. The cardiovascular and neurological criminately to all vasoconstrictors. How- In October 2012 the U.S. adverse effects of vasoconstrictive ever, it could be applied to certain prod- Food and Drug Administra- decongestants (ephedrine, naphazoline, ucts prone to misuse” (our translation) tion published an analysis of oxymetazoline, phenylephrine, pseudo- (4,6). 96 cases of accidental ephedrine and tuaminoheptane) used to While measures aimed at limiting mis- ingestion of vasoconstrictive nasal decon- relieve symptoms of the common cold use of medicines are welcome, they are gestants and eyedrops by children, report- are well known (1,2). In France, nasal in no way sufficient in the present case. ed between 1985 and 2012. The drugs preparations have been placed on List II Patients must be protected from the life- involved were intended for the relief of of moderately dangerous substances threatening adverse effects of vasocon- nasal congestion or ocular hyper- and are therefore available by prescrip- strictive decongestants used to treat aemia (1). tion only, while oral forms are available simple colds, and simple market with- The ingested substances were tetry- without a prescription. drawal is the best option. zoline, oxymetazoline or naphazoline Since the 1990s, several pharmaco - This procrastination further illustrates (combined with methylthioninium chlo- vigilance reports on these drugs have ANSM’s incapacity to take timely deci- ride in eye drops and with prednisolone in been published in France, and all have sions on drug safety and thereby to ful- nasal solution).
    [Show full text]